Human parathyroid peptide treatment of vertebral osteoporosis.
Previous studies have shown that treatment with daily injections of human parathyroid peptide (hPTH) 1-34 increase axial cancellous bone mass partially at the expense of peripheral cortical bone. In the present work the same hPTH 1-34 regime given for 12 months has been combined with oestrogen or nandrolone therapy to control peripheral bone resorption. Spinal and iliac cancellous (but not cortical) bone increased by 40%-50% above initial values while no perceptible changes occurred in radial cortical or cancellous bone. The evidence of radiokinetic and histomorphometric studies performed before and in the last months of treatment suggested that bone remodeling had proceeded through a transient anabolic phase with increased activation, but that activation had become normal after 11-12 months in the cancellous bone of the ilium whereas it continued to be raised elsewhere in the skeleton. It is concluded that in combination with oestrogens, hPTH peptides given daily injections hold great promise for the treatment of patients with osteoporosis who have already lost substantial amounts of spinal cancellous bone.
Reeve
J
J
Northwick Park Hospital, Harrow, UK.
Arlot
M E
ME
Bradbeer
J N
JN
Hesp
R
R
Mcally
E
E
Meunier
P J
PJ
Zanelli
J M
JM
D015502:Absorptiometry, Photon; D015519:Bone Density; D001842:Bone and Bones / Q000473:pathology; D002118:Calcium / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D010012:Osteogenesis; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use*; D013122:Spinal Diseases / Q000188:drug therapy*; D013326:Strontium Radioisotopes; D019379:Teriparatide; D014057:Tomography, X-Ray Computed
D010281:Parathyroid Hormone; D010446:Peptide Fragments; D013326:Strontium Radioisotopes; D019379:Teriparatide; D002118:Calcium